Phase 2 trial of bezuclastinib for SM partially completed
The phase 2 Apex trial aiming to test bezuclastinib in patients with SM, has recently completed enrollment for part one of the trial.
The phase 2 Apex trial aiming to test bezuclastinib in patients with SM, has recently completed enrollment for part one of the trial.
A recently published study showed those with Hymenoptera venom allergy (HVA) should be screened for clonal mast cell diseases (CMD).
According to a recently-published article, increased knowledge and awareness of systemic mastocytosis is needed among specialists.
A patient was diagnosed with aggressive SM due to findings from computerized tomography (CT) and contrast-enhanced PET scans.
A recent case report details a patient with mast cell leukemia (MCL), which authors state may be the rarest form of systemic mastocytosis (SM).
A case of patient with osteoporosis and systemic mastocytosis (SM) has highlighted the treatments available and the need for more data.
The cellular changes that occur in the liver of patients with systemic mastocytosis (SM) have been described in a recent study.
A recent report describes a patient with undiagnosed systemic mastocytosis who experienced unexpected complications during heart surgery.
Two cases involving patients with systemic mastocytosis (SM) without KIT mutations (KIT negative) have been recently reported.
Desensitization to isatuximab allergy in patients with ISM appears possible, according to a recent report.